dVise

Self-administration devices for injectable therapies

We deliver pen and autoinjector platforms that make treatment easier for patients and simpler for pharma teams to evaluate, integrate and bring to market.

Self-administration devices for injectable therapies

We deliver pen and autoinjector platforms that make treatment easier for patients and simpler for pharma teams to evaluate, integrate and bring to market.

Self-administration devices for injectable therapies

We deliver pen and autoinjector platforms that make treatment easier for patients and simpler for pharma teams to evaluate, integrate and bring to market.

Self-administration devices for injectable therapies

We deliver pen and autoinjector platforms that make treatment easier for patients and simpler for pharma teams to evaluate, integrate and bring to market.

We make self-medication simple, safe and accessible for patients by turning complex injectable therapies into intuitive, reliable self-injection devices.

Faster to market

Regulatory-ready device platforms that shorten the path from molecule evaluation to launch.

Best value offering

High quality devices enabling affordable treatments

Flexible capacity

Facility planned to scale from pilot runs to high-volume manufacturing.

Proven quality

Established devices, produced to international standards

Flexible capacity

Facility planned to scale from pilot runs to high-volume manufacturing.

Proven quality

Established devices, produced to international standards

Self-injection devices for the most common dosing needs

View product

See pre-validated molecules

vPush

Disposable pen platform for high-frequency self-injection with variable dosing, such as insulin or GLP-1 therapies.

COMING SOON

vTouch

Next-generation touch-activated delivery system currently in development.

COMING SOON

vAuto

Auto-injector platform for infrequent or single-use applications.

Start from a ready-made platform, or tailor one to your needs

Pre-validated packages

Regulatory-ready device platforms in development for selected molecules including testing, documentation to give your team a shorter path to adopt.

Insulin

Liraglutide (GLP-1)

Semaglutide (GLP-1)

Somatotropin (HGH)

Teriparatide

Follitropin alfa (FSH)

Expected availability: end of 2026 / start of 2027

Custom adpatations

For molecules or use cases outside the pre-validated paths, the platform is tuned to your molecule.

The process from early evaluation to scale up support

Early evaluation

Review of molecule, formulation, viscosity, dosing pattern and target markets.

Early evaluation

Review of molecule, formulation, viscosity, dosing pattern and target markets.

Early evaluation

Review of molecule, formulation, viscosity, dosing pattern and target markets.

Feasibility and fit

Check whether one of our platforms and planned packages is a good fit. If not, outline the custom work needed.

Feasibility and fit

Check whether one of our platforms and planned packages is a good fit. If not, outline the custom work needed.

Feasibility and fit

Check whether one of our platforms and planned packages is a good fit. If not, outline the custom work needed.

Device integration and testing

We agree on the integration work and test plan – from force and speed tuning to PFS / cartridge and human-factors checks.

Device integration and testing

We agree on the integration work and test plan – from force and speed tuning to PFS / cartridge and human-factors checks.

Device integration and testing

We agree on the integration work and test plan – from force and speed tuning to PFS / cartridge and human-factors checks.

Final documentation and scale-up

Support for combination-product documentation and preparation for tech transfer and future commercial production.

Final documentation and scale-up

Support for combination-product documentation and preparation for tech transfer and future commercial production.

Final documentation and scale-up

Support for combination-product documentation and preparation for tech transfer and future commercial production.

Merging Eastern and Western strengths to serve pharma better

Our team works across Europe and India, combining injection-device and regulatory experience.

Dominik Vonier

CEO

dominik.vonier@dvise.com

Chris Muenzer

COO / CTO

chris.muenzer@dvise.com

A new facility under construction in Sri City

Quality built for regulated work

Facility build-out follows ISO 13485 principles with automated assembly, clean-room areas and controlled environments for critical device steps.

From pilot lots to high-volume supply

Around 8,000 m² of modular lines for pens and auto-injectors, scalable from pilot lots to roughly 30 million devices.

Precision for consistent performance

High-precision tooling and molding for tight tolerances and repeatable device performance across batches and programs.

hello@dvise.com